Novel Treatments for Rare Cancers: The U.S. Orphan Drug Act Is Delivering—A Cross-Sectional Analysis

Samankaltaisia teoksia

• Novel treatments for rare rheumatologic disorders: analysis of the impact of 30 years of the US orphan drug act
  Tekijä: Lutz, Thomas, et al.
  Julkaistu: (2016)
• Novel orphan medicines and abandoned pathways - the US Orphan Drug Act of 1983 and the impact on rare rheumatologic diseases and lysosomal storage disorders
  Tekijä: Ries, Markus, et al.
  Julkaistu: (2015)
• Thirty Years of Orphan Drug Legislation and the Development of Drugs to Treat Rare Seizure Conditions: A Cross Sectional Analysis
  Tekijä: Döring, Jan Henje, et al.
  Julkaistu: (2016)
• Pressure for drug development in lysosomal storage disorders – a quantitative analysis thirty years beyond the US orphan drug act
  Tekijä: Mechler, Konstantin, et al.
  Julkaistu: (2015)
• Ten Years after the International Committee of Medical Journal Editors' Clinical Trial Registration Initiative, One Quarter of Phase 3 Pediatric Epilepsy Clinical Trials Still Remain Unpublished: A Cross Sectional Analysis.
  Tekijä: Anette Lampert, et al.
  Julkaistu: (2016-01-01)